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Abstract
The European Medical Information Framework (EMIF) project, funded through the 
IMI programme (Innovative Medicines Initiative Joint Undertaking under Grant 
Agreement No. 115372), has designed and implemented a federated platform to 
connect health data from a variety of sources across Europe, to facilitate large scale 
clinical and life sciences research. It enables approved users to analyse securely 
multiple, diverse, data via a single portal, thereby mediating research opportunities 
across a large quantity of research data. EMIF developed a code of practice (ECoP) 
to ensure the privacy protection of data subjects, protect the interests of data shar-
ing parties, comply with legislation and various organisational policies on data 
protection, uphold best practices in the protection of personal privacy and informa-
tion governance, and eventually promote these best practices more widely. EMIF 
convened an Ethics Advisory Board (EAB), to provide feedback on its approach, 
platform, and the EcoP. The most important challenges the ECoP team faced were: 
how to define, control and monitor the purposes (kinds of research) for which fed-
erated health data are used; the kinds of organisation that should be permitted to 
conduct permitted research; and how to monitor this. This manuscript explores those 
issues, offering the combined insights of the EAB and EMIF core ECoP team. For 
some issues, a consensus on how to approach them is proposed. For other issues, a 
singular approach may be premature but the challenges are summarised to help the 
community to debate the topic further. Arguably, the issues and their analyses have 
application beyond EMIF, to many research infrastructures connected to health data 
sources.
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1 Introduction
1.1  The EMIF Project
EMIF, the European Medical Information Framework (2013–2018), was a multi-
disciplinary research and development project. Its objectives were developing and 
implementing robust and scalable models to connect health data from a variety of 
sources across Europe to facilitate large scale clinical and life sciences research.1 
Creation of a common, federated data platform and a governance framework for the 
identification, assessment and (re)use or repurposing of health data can maximise 
the scientific research value that can be derived from health data, whilst protecting 
patient privacy. EMIF is funded2 through the Innovative Medicines Initiative (IMI),3 
a public private research and development partnership between the European Com-
mission and the European Federation of Pharmaceutical Industries and Associations 
(EFPIA).4
The EMIF Platform provides an efficient integrated information framework for 
the large-scale re-use of health and life sciences data. The Platform enables data 
users and data custodians to collaborate throughout the research lifecycle from 
data discovery to data sharing and data analysis. It enables approved users to ana-
lyse securely multiple, diverse, data via a single portal, thereby mediating research 
opportunities across a large quantity of research data. The EMIF project includes 
two specific research topics that have helped to guide the development of the Plat-
form: the identification and validation of protective and precipitating factors for 
conversion to Alzheimer’s Disease, and predictors of metabolic complications of 
obesity. The two clinical research sub-teams have started to publish results from 
EMIF-supported big data research (for example5,6).
The EMIF Platform supports federated analysis, and does not itself hold the 
research data being queried by its users. A research user transmits an analysis query 
(in a defined computable form) to multiple connected data sources, which will each 
execute the query on their own database or on a standardised,7 mapped, common 
data model extracted from their original database, and return to the requester only 
the query results, which might be, for example, as simple as a frequency distribution. 
Because data originating from multiple sources may have different formats, coding 
1 http://www.emif.eu, viewed 19 January 2018.
2 Grant number 115372.
3 The Innovative Medicines Initiative 2016, n.d., viewed 19 January 2018, http://www.imi.europ a.eu.
4 https ://www.efpia .eu, viewed 19 January 2018.
5 Vaudano E, Vannieuwenhuyse B, Van Der Geyten S, van der Lei J, Visser PJ, Streffer J, Ritchie C, 
McHale D, Lovestone S, Hofmann-Apitius M,Truyen L, Goldman M. Boosting translational research 
on Alzheimer’s disease in Europe: The Innovative Medicine Initiative AD research platform. Alzheimers 
Dement. 2015 Sep;11(9):1121-2.
6 Roberto G, Leal I, Sattar N, Loomis AK, Avillach P, Egger P, et al. (2016) Identifying Cases of Type 2 
Diabetes in Heterogeneous Data Sources: Strategy from the EMIF Project. PLoS ONE 11(8): e0160648.
7 The OMOP Common Data Model https ://www.ohdsi .org/data-stand ardiz ation /the-commo n-data-
model /, viewed 19 January 2018.
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and content, the Platform harmonises the data according to accepted semantic stand-
ards, in this case via the Observational Medical Outcomes Partnership (OMOP) 
common data model, to enable the consistent execution of the analysis queries.8
This approach, which can be fully or partially automated depending on what is 
acceptable to each data custodian, enables queries on multiple repositories without 
having to transfer any subject level data between the parties. In cases where multiple 
data extracted need more in depth processing (such as linkage), EMIF offers a kind 
of secure data haven, a Private Remote Research Environment (PRRE), temporarily 
to host and protect the data. Alternatively, trusted third parties may be contracted to 
host an extracted research dataset (on a temporary basis) on behalf of a research user 
and one or more data sources, by mutual agreement.
The EMIF project is transitioning into a sustainable entity post IMI, with a com-
mon data platform supportive of European real-world research. Underpinning this is 
the work conducted on the platform development, and the experience within Alzhei-
mer’s and the metabolic complications of obesity, but for a disease agnostic service 
provision in the future.
Some key learning from within the EMIF project has been facilitated by specific 
research use cases, and in particular outlining the current processes involved in con-
ducting real world research. This was illustrative of the inherent challenges with ref-
erence to administrative overheads, methodological tensions, and time to an answer.
Of importance for this paper, alongside technical considerations for the EMIF 
platform development, EMIF has developed a practice-based governance frame-
work, the ethical code of practice (ECoP), to assure the local provenance of source 
data within a federated network. This is also envisaged to provide more wider guid-
ance, via the ECoP, beyond the auspices of the EMIF project, to the European health 
data research community.
1.2  The EMIF Ethical Code of Practice
Despite the relative separation between research users and subject level data, it was 
important that the design and operation of the EMIF Platform be governed by the 
ECoP to protect the interests of all parties. The goals in developing the ECoP were 
that the EMIF Platform and its services are used in ways that comply with legislation 
and various organisational policies on data protection, that EMIF upholds best prac-
tices in the protection of personal privacy and information governance, and eventu-
ally that EMIF could promote best practices in the conduct of clinical research using 
health data, for the general (public) interest.
Importantly, EMIF needs to ensure compliance with the European Directive 
95/46/EC of 24 October 1995 on the protection of individuals with regard to the pro-
cessing of personal data and on the free movement of such data. Given its imminent 
8 Cunningham JA, Van Speybroeck M, Kalra D, Verbeeck R. (2016) Nine Principles of Semantic Har-
monization. AMIA Annu Symp Proc 2016:451–459.
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enforcement, it is equally important for the ECoP to comply with the new General 
Data Protection Regulation 2016/679.
EMIF is not alone in seeking to develop an integration environment that provides 
research access to collections of data sources in acceptable ways. Several European 
countries are also building such integrated research capability at national levels. 
However, EMIF has been the largest scale Europe-wide initiative seeking to do this, 
and its ECoP may be the most advanced work to date on the governance of a feder-
ated big data research infrastructure.
In developing the ECoP, several pre-existing codes and policies were examined 
during 2014–2015 to evaluate whether component parts of these should be adopted 
by EMIF. The most relevant examples studied were:
• The IMI Code of Practice on secondary use of medical data in scientific research 
projects.9
• The ENCePP Code of Conduct10 and checklist.11
• UK Medical Research Council (MRC) Policy and Guidance on Sharing of 
Research Data from Population and Patient Studies.12
• Yale University Open Data Access (YODA) Project Procedures to Guide Exter-
nal Investigator Access to Clinical Trial Data.13
• The EHR4CR Standard Operating Rules14 and Consent Model and Trust 
Model.15
• SUMMIT (IMI/115006) Principles for Data Sharing.16
• ISO 22221: 2006—Good Principles and Practices for a Clinical Data Ware-
house.17
• International Committee on Harmonization Topic E 6 (R1) Guideline for Good 
Clinical Practice (Step 2, 2015).18
• The World Medical Association Declaration of Helsinki.19
10 Available from http://www.encep p.eu/code_of_condu ct/docum ents/ENCeP PCode ofCon duct.pdf.
12 https ://www.mrc.ac.uk/publi catio ns/brows e/mrc-polic y-and-guida nce-on-shari ng-of-resea rch-data-
from-popul ation -and-patie nt-studi es/.
13 http://yoda.yale.edu/polic ies-proce dures -guide -exter nal-inves tigat or-acces s-clini cal-trial -data.
14 http://www.i-hd.eu/i-HD/asset s/File/EHR4C R/deliv erabl es/11518 9_EHR4C R_D1_4%20-%20fin 
al%20sce nario s%2C%20sta ndard %20ope ratin g%20rul es%20for %20the %20EHR 4CR%20-%20COM 
PLETE .pdf.
15 http://www.i-hd.eu/i-HD/asset s/File/EHR4C R/deliv erabl es/11518 9_EHR4C R_D9_17%20-%20The 
%20EHR 4CR%20Con sent%20and %20Tru st%20Mod el.pdf.
16 SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools, 
http://www.imi-summi t.eu
17 https ://www.iso.org/stand ard/40783 .html.
18 https ://www.ich.org/filea dmin/Publi c_Web_Site/ICH_Produ cts/Guide lines /Effic acy/E6/E6_R2__
Adden dum_Step2 .pdf.
19 https ://www.wma.net/polic ies-post/wma-decla ratio n-of-helsi nki-ethic al-princ iples -for-medic al-resea 
rch-invol ving-human -subje cts/.
9 Bahr A and SchlünderI, 2015, Code of practice on secondary use of medical data in European sci-
entific research projects. International Data Privacy Law, vol. 5(4): 279–291. http://dx.doi.org/10.1093/
idpl/ipv01 8.
11 http://www.encep p.eu/code_of_condu ct/docum ents/Annex 2_Check list.pdf.
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In practice, none were found directly to target the federated model of big health 
data research, although EMIF does adhere to the IMI Code, which contains many 
high-level principles that the ECoP could extend with more operational detail. Many 
of the instruments focused on principles for bilateral data sharing agreements, and 
primarily on the scientific validity of a proposed investigation (factors such as statis-
tical power) rather than measures to protect data subject privacy.
Successive drafts of the ECoP were developed during 2014–2016, primarily by 
a core team of academic, healthcare, pharma industry and legal experts, with peri-
odic wider consultation within the consortium comprising many data custodians, 
research users and patient organisations across Europe. A further layer of consulta-
tion occurred through presentations of the evolving work, and key issues at Euro-
pean and international conferences, and contributions to academic publications.20,21 
The ECoP specifies rules for the appropriate conduct of research users, data provid-
ers and any intermediate brokers such as EMIF, when undertaking research using 
big and/or federated health data sets. It focuses on respectful data use and on the 
protection of data subject privacy. It is still in an advanced draft status, and it has not 
yet been published.
In order to provide external validation of the ECoP, and to benefit from additional 
independent expertise outside the consortium, EMIF convened an Ethics Advisory 
Board (EAB) in 2015. Members include some of the authors of this article: […].
The Board members reviewed and provided feedback on the EMIF project and 
the role of the Platform, the federated model of providing query access to data cus-
todians, and on specific details in the ECoP. In particular, EMIF sought advice from 
the EAB members on several key issues for which there appeared as yet to be no 
clear consensus on good or acceptable practice within the field.
The most important challenges the ECoP team faced were: how to define, con-
trol and monitor the purposes (kinds of research) for which federated health data 
are used; the kinds of organisation that should be permitted to conduct permitted 
research; and how to monitor this. More specifically:
• how to define publicly acceptable (“bona fide”) research—intended for general 
(public) interest, with specific challenges around the definition of the general 
interest, in the context of health and health care, and making research results 
publicly available, either directly, or indirectly via medical products;
• how to define bona fide research organisation, including the acceptability of 
commercial versus non-commercial organisations, noting that some data custo-
dians have a reluctance to share data with industry or may not share data at all, 
being limited to providing results of in-house analyses only;
20 Lea NC, Nicholls J, Dobbs C, Sethi N, Cunningham J, Ainsworth J, Heaven M, Peacock T, Peacock 
A, Jones KH, et al. Data Safe Havens and Trust: Toward a Common Understanding of Trusted Research 
Platforms for Governing Secure and Ethical Health Research. Journal of Medical Internet Research 
2016;4(2):e22. https ://doi.org/10.2196/medin form.5571.
21 Kalra, D., Stroetmann, V., Sundgren, M., Dupont, D., Schlünder, I., Thienpont, G., Coorevits, P., and 
De Moor, G. (2016) The European Institute for Innovation through Health Data. Learning Health Sys-
tems, https ://doi.org/10.1002/lrh2.10008 .
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• how to monitor and detect misuse of the EMIF Platform and what form of sanc-
tions can be applied, if any;
• how to balance a need for transparency (and to which stakeholders) about how 
data repositories have been used and by whom, with the (possibly also commer-
cial) sensitivity about research undertaken during product design and develop-
ment.
The rest of this paper explores those topics, offering the combined insights of the 
EAB and EMIF core ECoP team. For some issues we have been able to propose a 
consensus on how the field should approach an issue. For other issues we believe 
that it is premature to propose a singular approach and so we have summarised the 
challenges in a structured way to help the community to debate the topic further. 
The discussion points are expressed in terms of their application to the EMIF con-
text, but we believe that these issues and their analyses can apply to many other 
research infrastructures connected to health data sources.
2  Constraints and Good Practices on “Commercial Uses” of Health 
Data
2.1  Defining Bona Fide Research
There appears to be a generally supportive attitude by individuals towards the use 
of their health data for scientific research. However, the media, patient organisa-
tions, and a number of data custodians regularly express concern about the use of 
health data by commercial organisations, especially when data are collected through 
public institutions and using public funds. Frequently the public debate tends to 
focus on whether the organisations using the data are commercial, rather than on 
the purposes for which the data are to be analysed, and on how the results are to be 
used (ref. Wellcome study 2016). This problem is exacerbated when data are shared 
across different national and sub-national research cultures, which often operate in 
widely diverse value environments. In Germany for instance, more than 60 universi-
ties incorporated a “Zivilklausel” in their constitution, also adopted by the Higher 
Education Law of several German regions, that outlawed all research cooperation 
with the military sector, including military medical research. Blanket cooperation 
and data sharing prohibitions are arguably inconceivable in the UK. In this context, 
EMIF has attempted to define the concept of bona fide research as a way of specify-
ing the kinds of research use that society and data custodians are most likely to find 
acceptable, and to constrain use of EMIF-brokered and EMIF-facilitated research 
only to bona fide research purposes.
Against this background, the authors have concluded that it is necessary and 
appropriate to define and constrain the use of EMIF services to “socially acceptable” 
1 3
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forms—what we have termed bona fide research22—in order to articulate the prin-
ciples on which EMIF operates and subsequently to address public concerns about 
the use of health data. This approach seems appropriate, provided it does exercise 
a clearly-defined discrimination on the suitability of organisations to conduct bona 
fide research. Three comments may further clarify the issue.
First, defining bona fide research as precisely as possible can help in complying 
with the purpose specification principle in data protection law with regard to the dis-
tinction between commercial and non-commercial research.
Second, the problem remains whether the focus here should be on institutions 
and organisations or on their activities. The former approach has been adopted, for 
example, in the context of the text data mining (TDM) exception (more on this later) 
by the European Commission in its legislative proposal of September 14th, 2016 on 
copyright in the Digital Single Market. It seems easier to manage, but it might pre-
vent some socially beneficial activity (e.g., research done by an insurance company 
to minimise premium discrimination) and allow others that might be less welcome 
(e.g., universities carrying out market research for its own courses or for an exter-
nal company). The latter approach has been adopted by the General Data Protection 
Regulation. This carves out exemptions for scientific, historical, and health research, 
adopting a broad notion of research that encompasses activities of public and private 
entities alike (cf. recital 159). This approach is sensible, but it may be more dif-
ficult to manage, especially for a large and complex organisation in which bona fide 
research is only one of its activities, since it would need to ring-fence the knowledge 
gathered from conducting the research to those parts of the organisation effecting 
the permitted purposes.
Third, qualifying research as bona fide, socially acceptable, effectively stating 
which kind of research one considers appropriate, avoids addressing the question 
whether EMIF should be equally open to research conducted by commercial for-
profit companies and by publicly funded not-for profit organizations.
With this framework and the aforementioned provisions in mind, the characteri-
zation of bona fide research supported and endorsed by all the authors of this article 
is the following:
Research qualifies as bona fide whenever its ultimate goal is to discover new 
knowledge intended for the general interest in health and to be made publicly 
accessible (e.g., published in scientific journals or disseminated through digi-
tal media) without undue delay.
2.2  New Knowledge Intended for the General Interest in Health
This characterisation deserves some comments to be clarified.
22 For some helpful definitions of bona fide research already available please see: http://www.nshd.mrc.
ac.uk/data/data-shari ng/meta-data-repos itory /bona-fide-resea rch/.
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First, this is indeed a characterisation and not a definition. It does not provide 
necessary and jointly sufficient conditions, but rather a guideline for an intelligent 
and sensible handling of personal data.
Second, the characterisation avoids using the more common phrase “intended for 
the public good” because it is notoriously difficult to determine (let alone predeter-
mine) exactly what is intended by a specific use of health data, and what the public 
good of it may be. Note that the literature on health data usually refers to “public 
good of health knowledge” not just the “public good”. Furthermore, as it is well 
known, in economics, “public good” is a technical term to refer to a good that is both 
non-excludable (individuals cannot be effectively excluded from its use) and non-
rivalrous (use by one individual does not reduce availability to other individuals). 
This is not the sense in which “public good” should be understood in the context of 
EMIF-related research, hence the preference for the use of “general interest” instead. 
This is still a technical expression, but one which is more common in legal contexts, 
and of which authoritative interpretations exist by the highest courts in Europe (e.g., 
CJEU and ECHR). In the same vein, the GDPR uses the term “public interest” to 
qualify tasks the performance of which may require certain forms of data processing 
without consent or to delineate the scope of “archiving purposes” for which specific 
exemptions apply (e.g., Art. 6, al.1 (e); Art. 9, al.2 (i) and (j); Art. 14, al.5 (b), etc.).
Third, referring to the “general interest” as the ultimate goal that should orient 
any bona fide research has the further advantage of focusing on the purposes for 
which the data are being used (although such a notion of purpose should not be 
linked necessarily with the purpose specification principle occurring in EU data 
protection law). Such a purpose-centred approach enables one to exclude all uses 
of EMIF services that do not intend to attain the general interest, e.g. mere market 
research.
Finally, the qualification of the goal as “ultimate” may seem redundant but it is 
actually intended here to allow research that, for example, improves a method, or 
the understanding of how medical research works (e.g. from a sociological perspec-
tive), which then, only in a next step, may lead to, for example, better drugs or a 
better way to develop medical research (although in both cases one could argue that 
they are captured by “knowledge” and “public interest” if they are suitably widely 
interpreted). We are aware that there may be a problem with some kinds of research 
exemption insofar as this may presuppose some kind of idealisation or typical notion 
of research that is very much based on basic science or medicine, while in fact there 
is also sociological, ethical, legal etc. research that might equally benefit from EMIF 
data (e.g. a meta-study on profiles of people who volunteer for research) and which 
should not be excluded, even though its “benefits” may be more diffuse and indirect.
The characterisation of bona fide research specified above is intended to 
exclude uses such as market research and intelligence gathering that might be 
exploited for targeted sales purposes. Recent research in the UK, yet to be pub-
lished, also highlights public concern about the use of health data that leads to 
discriminatory (e.g. life insurance) practices or which informs cuts in health 
services.23 Data custodians and public attitudes indicate that these are the least 
23 https ://www.herc.ac.uk/get-invol ved/citiz ens-jury/.
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acceptable uses of population health data. Even when faced by strong counter-
arguments, usually formulated in terms of creation of wealth or improvement of 
security measures, we remain in favour of excluding such uses. Admittedly, the 
definition of bona fide research brings about some possible indeterminacy. How-
ever, with a clear focus on functions and purposes of the organisation, rather than 
on its nature (see below 2.3 on the notion of commercial research and profits), it 
should be possible to deal with such an indeterminacy in ways that are satisfac-
tory both scientifically and ethically. The orienting aim in every decision is to 
ascertain whether data obtained through EMIF services are used in the general 
interest and specifically the general interest in health. From this perspective, it is 
right to exclude some purposes. More specifically, the following broad areas of 
data uses may easily be problematic:
(1) Market research and intelligence gathering. If data could eventually also be 
used for unacceptable (or indeed illegal) non-health purposes—such as using 
the data to make insurance or employment decisions that affect the data subject, 
e.g. denying employment to people who participated in a study, or increase their 
health premiums—then such uses should always be excluded explicitly.
(2) Military (or defence) research or applications focused on weapons development. 
Although attitudes differ quite widely in Europe on the appropriateness for aca-
demics to be involved with weapons research, any use of EMIF data should be 
strictly non-military in all its aspects and derivations. However, it is important 
to distinguish military weapons-related research from research seeking to derive 
knowledge to improve the health and care of military personnel, for example 
if injured in field situations or having been exposed to biological weapons. It 
needs to be remembered that military research may be medical in nature, such as 
healthcare innovations that originated in the military environment e.g. in acute 
trauma surgery, and also in the domain of public health e.g. pandemic epidemiol-
ogy. Military health systems sometimes care for families of military personnel 
and veterans.
(3) Algorithms training. This is a growing area of difficult issues and—in light of the 
potential benefits but also risks involved and the fast-developing technologies at 
stake—it is likely that additional requirements set by EMIF or the requirements 
at the users’ institution may not be sufficient. In this case too, the ultimate goal 
of serving the general interest of the public in health remains an essential guide.
The previous three areas should not be interpreted as exhaustive, nor as exclud-
ing all non-health research. The latter may still be considered valid research 
based on health data especially when this concerns studies into the effectiveness 
of a drug to decide whether it should be included in a health plan. The reason-
able concern is that similar studies may end up harming the very people whose 
data are being used to develop them. And indeed, people should be able to par-
ticipate in research without having to fear that the outcome may harm them or 
their group. Nevertheless, as shown by the National Institute for Health and Care 
Excellence (NICE) in the UK, for example, these types of effectiveness studies 
 L. Floridi et al.
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can and should be part of the licensing regime, while safeguarding the patients 
whose data are being used. The fundamental point remains that, in similar cases, 
data are used in “socially beneficial” ways, to decide an equitable way to allocate 
resources and distribute advantages and costs amongst a solidarity group.
2.3  New Knowledge Intended to be Made Publicly Accessible
The incorporation of research results into a product that is then made available 
(sold) to health systems is a way of translating research results into practice and 
eventually making them available to people who need it. If this is the case, then 
EMIF may not always require that the actual results of the analyses performed be 
published in a scientific outlet. However, making research results public is essen-
tial, since bona fide research is linked to the idea of general interest. So “produc-
tisation” alone, especially in the form of patents, may not always be sufficient to 
satisfy the characterisation of bona fide research. This does not mean that concerns 
about “productisation” are always valid prima facie as such, but it does mean that 
more often than not mere productisation cannot count as making knowledge publicly 
accessible—for the simple reason that the knowledge that went into the product can-
not always be inferred from the product—and that in such cases publication should 
be mandatory, at least dissemination in some additional form. On the other hand, the 
“publication” does not have to be in a peer-reviewed journal. It is a matter of pub-
lic access to available knowledge. Some form of dissemination stating whether and 
how results of the analyses were used may suffice. Demanding a form of feedback 
or public acknowledgement may also be appropriate, as well as the availability of 
a “public service” for possible future improvements. If “productisation” involves a 
patent, as it is often the case, then a publication could still be made available, given 
that a fair balance between public benefit and monopoly is exactly what the patent 
system tries to achieve. Indeed, the general interest may be better served by both the 
availability of the product and the sharing of the knowledge, so one should strive 
to make both available. Of course, there could be exceptions, e.g. if the product is 
a software programme (e.g., an app for some wearable digital system). As a good 
example consider that in the BRAINS (a database with brain scans) project, a short 
report is required on how the data were used, but that is only partly (or to a small 
degree) for the benefit of the public. The purpose is mostly to prove the value-for-
money to funders. Finally, in setting best practice standards one should avoid facili-
tating the perpetuation of unpublished negative results.
2.4  Legal Compliance is a Prerequisite
As a matter of principle, there is no connection between the existence of data subject 
consent (e.g. cohort study data versus extracted hospital EHR data) and how EMIF 
defines or applies bona fide rules because consent precedes logically and determines 
legally any uses of data that EMIF should make possible. A clear example of such 
law-abiding use of personal data is given by techniques of pseudonymisation. More-
over, since one should take into account the processing of big data, it is possible 
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that differential privacy-techniques could be useful in this context (Roth and Work 
2014). As bona fide research is the kind of research that meets ethical requirements, 
EMIF does not (have to) add anything over and above that. However, since EMIF 
seeks to protect the interest of all parties connected to its data federation (data cus-
todians and data users), and the reputation of EMIF as a trusted research platform, 
EMIF’s ECoP does place an obligation and expectation on parties involved in a data 
sharing interaction to verify themselves that the intended research complies with any 
applicable data subject consent and with any necessary research ethics approvals. 
This implies that only data that have the appropriate consent and approval can be put 
into the original source database, and they can only be used for the uses within the 
existing consents’ and approval parameters.
3  Constraints in Relation to Type of Organisations
3.1  Defining Bona Fide Research Organisations
As a further level of assurance to the public and to data custodians, we have supple-
mented the above restrictions of use for bona fide research with a restriction of use 
only by bona fide research organisations, which we have characterised thus:
any organisation appointed or accredited or funded to undertake bona fide 
research, and/or which has made public its commitment to adhere to recog-
nised research governance principles.
Non-acceptable kinds of organisation follow as a consequence of the characteri-
sation of bona fide research. Rather than a list of such kinds, it is preferable to focus 
on their functions and their ways of using data. Still, some illustrations of what rep-
resentative kinds of organisation are not acceptable would be helpful for explanatory 
and illustrative purposes. The examples may also help to gain public acceptance.
A grey area left unspecified by the characterisation above is represented by “dual 
nature” organisations, which today would include many commonplace institutions 
such as public universities. According to the characterisation of what counts as a 
bona fide organisation, it is not a requirement that bona fide research is the primary 
business of that organisation, or that all of the research undertaken by that organi-
sation and that is unrelated to EMIF data is published. It is also not a requirement 
that the organisation is publicly funded. Pharmaceutical companies are not the only 
commercial entities that might become EMIF users: medical device manufactur-
ers, the insurance industry, health clubs and private healthcare providers might also 
be EMIF commercial users conducting bona fide research. Conversely, publicly 
funded bodies such as universities sometimes undertake commercially sponsored 
research, for example as a consultancy. They also occasionally spin out publicly-
funded research into a company to commercially exploit the results. The objective 
in proposing and using the characterisation above is to apply sensible and informed 
discernment on the basis of the function of the organisation rather than its nature, 
i.e., whether it is a public body or not, or a not-for-profit or a for-profit organisation. 
It is crucial to include all and only the “right” (intended) types of organisation. For 
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example, excluding science journalism trying to scrutinise the way medical research 
is done should be seen as an unwelcome form of censorship.
The definition provides the right approach, as it is, at least for the time being, 
sufficiently clear and broad. However, given the ramifications of GDPR, bona fide 
organisations must have a Data Protection Officer, who is overlooking the respon-
sible processing and management of personal data and, at least in certain cases, the 
equivalent of an Ethics Advisory Board or at least access to such, which may be an 
external Ethics Committee.
3.2  The Discussion on Commercial v. Non‑commercial, Non‑profit v. for‑Profit
Given the previous clarifications, it may be tempting to emphasise and use—as the 
basis for regulating access to data sources connected through EMIF services—the 
previous two characterisations of bona fide research and bona fide research organisa-
tions as if they simply overlapped with the distinction between commercial vs. non-
commercial research and non-profit vs. for-profit organisations. This overlap may 
even be defensible to public scrutiny and public opinion. But it would be too sim-
plistic and in the end incorrect. The criterion of commercial versus non-commercial 
research, or for-profit versus non-profit organisations, is actually not very helpful 
or pertinent, as also research carried out for commercial reasons, or by commer-
cial organisations, can be (and usually is) very beneficial for society as a whole. A 
very similar discussion took place in the context of the 2014 expert group report on 
standardisation in the field of text and data mining (Hargreaves et al. 2014), where 
the question arose whether a copyright exception should be introduced for text and 
data mining (hereafter ‘TDM’) research purposes, and if so, whether this exception 
should cover only non-commercial or also commercial research. The conclusion 
of the expert group was that such distinction would slow down innovation and be 
very difficult in practice (p. 67: “Moreover, as we have argued in the economics sec-
tion of this report, it does not make sense from a strictly economic point of view to 
distinguish between the commercial and the non-commercial. […] A TDM excep-
tion applying to all scientific researchers, commercial and non-commercial, would 
avoid most of these problems and would represent a huge improvement on the status 
quo.”). The text of the proposed Directive on Copyright in the Digital Single Market 
(European Commission, COM (2016) 593) is still under discussion, but the Euro-
pean Parliament (European Parliament, JURI Draft Report, March 2017) and the 
Council seem to endorse the definition of “research organisation” suggested by the 
Commission (Council Presidency Compromise, September 2017). Under that defini-
tion, only entities operating on a non-for-profit basis, or reinvesting all the profits in 
their scientific research, or acting pursuant to a public interest mission recognised 
by a Member State, qualify for the TDM exception (together with cultural herit-
age institutions). Although recital 10 explains that these organisations also benefit 
from the exception when they engage in public–private partnerships, the concept 
of “research organisation” is more limited than what we envisage in the definition 
of “bona fide research organisation” for EMIF. Nevertheless, the proposed Direc-
tive does not explicitly limit the exception to TDM for non-commercial research 
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(contrary to, for instance, the TDM exception in Section 29 of the UK Copyright, 
Designs and Patents Act 1988, introduced in 2014).
In our view, the distinction between commercial and non-commercial research is 
not the pivotal issue, given the purpose-centred approach indicated above, nor does 
the general for-profit nature of the organisation matter much, if the ultimate goal for 
which EMIF data are being used remains bona fide research as characterised above. 
For example, a company may develop bona fide research for the sake of improved 
public relations, to enhance their reputation, or in view of commercial benefits that 
may occur only indirectly.
3.3  Benefit Sharing and Exclusivity
Indeed, two related considerations are more crucial. One is benefit sharing (BeSh). 
The public opposes commercial interests when organisations appear to be exploit-
ing public funds or infrastructures (including data in this case), and when the BeSh 
arrangement is not fair. That is why it is important to demand a fair BeSh scheme 
if commercial and for-profit entities have access. Some of the research may already 
have benefit sharing obligations under the national legal framework under which it 
was conducted. In these cases, it would be up to the parties to ensure that these 
obligations are fulfilled and carried over into any collaboration that comes out of 
their EMIF engagement. Furthermore, it may be preferable to encourage such an 
approach and add a clause that recommends parties to consider appropriate BeSh 
arrangements (Vayena and Tasioulas 2016).
The other issue is exclusivity. Inevitably, as parties move towards commercialisa-
tion or productisation, a degree of exclusivity (e.g. through a patent) may be required 
or demanded. This may be problematic. Consider a partner making data initially 
available through EMIF, then brokering a connection that could lead to a product, 
but with the condition that the original study/data is no longer made available to 
other researchers or EMIF partners (this could be in order to gain a time advantage 
e.g. if more than one team work in that direction). In this case, we recommend, as a 
solution, a “perpetuity” clause stating that, once research data have been made avail-
able through EMIF, they should be accessible to all authorised research users irre-
spective of any specific research in progress or undertaken. The data should only be 
withdrawn from access if the grounds for making them available have changed (e.g. 
if an ethical approval or consent is reversed).
4  Oversight of Bona Fide Constraints
4.1  Auditing and Enforcing these Bona Fide Constraints
If the reputation of EMIF, the trust of data custodians, as well as the trust of the 
authorities and the public, substantially hinge upon access to EMIF services that 
is limited to bona fide research organisations and for bona fide research purposes, 
EMIF will be expected to assure itself and others that these conditions are met. In 
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principle, data sharing requests should be supported by approval of an ethical over-
sight body (at the requesting institution or obtained by the data custodian prior to 
undertaking the research investigation). Beyond that, however, the question still 
remains as to the further responsibility of EMIF. Some tensions arise here partly due 
to whether EMIF has an obligation to monitor and investigate the internal activi-
ties of EMIF users (such as pharmaceutical companies), and partly due to the fea-
sibility of such an obligation given cost issues, since large scale monitoring will be 
expensive.
Self-declaration is insufficient to enforce bona fide constraints. Something beyond 
pure self-declaration should be implemented, to avoid loss of credibility. Our view is 
that EMIF should have dedicated staff for this screening. A ‘light’ and complemen-
tary solution would be to set up a notice-and-action system, whereby EMIF users 
themselves can signal “inappropriate” organisations if they become aware of them 
(cf. flagging systems commonly used on social media). An intermediate solution, 
also compatible with the work of dedicated staff, would be to allow EMIF users to 
‘rate’ other users on the basis of the interactions they had with each other (cf. rating 
systems of auctioning websites like eBay). However, given that research groups may 
be in competition, peer rating might be motivated by interests that are not visible to 
EMIF. In both cases, signalling and rating would need to be independently assessed. 
In addition to peer mechanisms, data protection authorities and their strengthened 
powers on the basis of GDPR will play a major role in this context. Finally, there 
should also be obligations on the other end, that is, an appeals process against the 
decision, to avoid the danger of inadvertently creating unfair market advantage or 
monopoly to the detriment of an organisation that is “substantially similar” to one 
that has been allowed to participate.
It is not realistic to try to prevent a large organisation from sharing direct access 
to a research dataset, or indirectly sharing the research results, with departments and 
staff that are not conducting bona fide research, such as marketing departments. One 
should simply require that this is not done by contract when signing up to be an 
EMIF user, or perhaps by means of a regular self-declaration. One may then require 
periodically some form of evidence that the research results have only been used 
for permitted purposes. As a general strategy, one should regard the organisation 
as a whole as doing bona fide or non-bona fide research with EMIF data, otherwise 
the implementation would become unrealistic. It does not seem feasible to screen 
every contract, but it may be important to add a clause to the Terms and Conditions 
and the contract for use of the EMIF Platform, as just indicated. Note that the focus 
remains on the nature of the specific activity, not on the nature of the organisation 
(although the two are easily connected, it is the priority given to the former that mat-
ters, see above). The sanction would be the (temporary or permanent) exclusion of 
the whole organisation from having access to EMIF. Adding a clause to the effect 
that the data cannot be used for anything else than the intended purpose would mean 
that, if something goes wrong, the wrongdoers will be found to have violated the 
contract. Finally, in order to enforce bona fide constraints, terms and conditions of 
the EMIF platform shall make reference to GDPR provisions, such as Art. 40 on 
Codes of Practice and Art. 42 on certifications. In addition, Art. 55 on the powers of 
supervisory authorities should be taken into account. Whether or not EMIF can fully 
1 3
Key Ethical Challenges in the European Medical Information…
police enforcement mechanisms, this activity will be complemented by the enforce-
ment mechanisms of GDPR. On this basis, one can imagine further safeguards via 
external auditors, ethics certificates, and so forth.
Even if there is no routine provision of evidence, EMIF should retain powers to 
investigate any concerns about the use made of EMIF services by one of its user 
organisations, such as the authority to appoint an external auditor and a requirement 
that the organisation support (and pay for) the investigations of such an auditor. 
Such power is crucial. To cite an example: within the ethics management system of 
the Bavarian construction industry, a company has to undergo an audit every 3 years 
and pay for it in order to renew their ethics certificate. This is essential.
A range of sanctions can be applied by EMIF to a research organisation found 
to be in breach of its obligation only to conduct bona fide research. One may con-
sider suspending temporarily or permanently the license to use EMIF services. One 
may also envisage publishing a list of usage breaches, partly for transparency to the 
public, partly to act as a deterrent, and partly to ‘name and shame’. The problem is 
both legal and ethical. From an ethical point of view, EMIF should adopt ‘closed’ 
sanctions, such as a warning, or a temporary suspension—and in case of serious 
and repeated breaches, a permanent revoking—of the license to use EMIF services. 
However, from a legal point of view, ‘naming and shaming’ can be problematic, 
because issue of legal liability for reputational damage may arise. One should only 
‘name and shame’ if one proceeds in accordance with fair trial requirements (the 
party should be given a reasonable period to react and restore the breach, the deci-
sion should be open for appeal, etc.). We advocate in the Terms and Conditions 
of the EMIF Platform the possibility of some kind of mediation for serious cases 
whereby EMIF users accept the authority of an existing or ad hoc panel of mediators 
and are willing to bear the costs. To give an analogy, the ethical ‘sanctions’ would 
be comparable to the peer review system, which is good at many issues but less good 
at spotting fraud and ultimately relies on the honesty of the partners. It is preferable 
to acknowledge clearly this reliance than hide it behind grand-sounding but unen-
forceable provisions. Of course, legal sanctions remain a possibility but they are a 
different issue (e.g. enforcement of current legal rules on data protection). A ques-
tion to be addressed is how transparent the ethical sanctions should be. At minimum 
EMIF could make public (e.g. via its web site) the action it is taking when a breach 
is identified, without naming the wrongdoer. This would have the further benefit of 
signalling that unethical uses will be identified and sanctioned.
4.2  Transparency of Access Requests
A final question that arises, is whether data custodians should be informed 
about every request for access to data they made available through EMIF, and 
if so, with which level of detail. In this context, a fair balance needs to be struck 
between commercial sensitivity arguments invoked by data users, who may wish 
to conduct research confidentially (even if the results may later be published), and 
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data custodians who may need to confirm adherence to any constraints they have 
placed on the permitted uses of their data.
One scenario, favoured by some of the EMIF data custodians we have con-
sulted, is that an audit report extracted from the query log is always accessible to 
authorised individuals within the data custodian organisation. This would allow 
inspection of which organisations have executed queries each day, on which cat-
egories of their data and with what parameters, and if any disclosure controls 
were applied. Since this would reveal the research areas being investigated by 
each research user, this access would need to be governed by a confidentiality 
agreement, with penalties for breach along the same lines as those described for 
research users above.
A second scenario, that might be acceptable to some data custodians, is for a 
filtered overview of analysis activity to be provided regularly to data custodians, 
with a more detailed audit log extract only produced if a concern is raised. Such 
a filtered overview report can be defended as the more usable approach. Because 
of this need for filtering, the system should make it technically possible to indi-
cate which constraints are attached to uses of certain datasets (otherwise the data 
custodian will run the legal risk of non-compliance). Online repositories such as 
SSRN, for example, frequently make public user statistics like “this paper has 
been seen/downloaded/cited X times” etc. Something similar could be envisaged. 
It would be sufficient to indicate to users that there is interest, and maybe patterns 
in that interest, as opposed to having detailed and explicit information about who 
is interested in what. In short, a balance should be struck between the commer-
cial sensitivity of some data users and the protection of data custodians. With a 
caveat: transparency is not the one-size-fits-all solution. For example, in addi-
tion to a trusted third-party audit (EMIF positions itself as a trusted third-party to 
audit query activity on behalf of the data custodians, instead of allowing the data 
custodians direct insight into the queries being run on their data), it is possible 
that some technical solutions will help us in this context, such as zero-knowledge 
proofs.
This is an area where there is a need for wider consultation with data custodi-
ans and research users on the appropriate level of activity transparency and the 
mechanisms for protecting commercial sensitivity, to balance the legitimate and 
understandable interests on both sides.
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